Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Community Trust Bancorp, Inc. (CTBI) is presenting at the Piper Sandler Financial Services Conference in Aventura, Florida on November 17, 2026. The company filed a formal investor presentation deck (Exhibit 99.1) containing current and historical financial results along with future performance goals.
Pro-Dex, Inc. entered into an amendment to its credit agreement with UMB Bank to consolidate the outstanding principal balances of two term notes into a single $8.51 million Term Note D. The amendment extends the maturity date to November 1, 2031, sets a fixed interest rate of 6.67% per annum, and extends the maturity of its revolving note to December 31, 2028.
Hancock Whitney M&A Deal with Trustmark Corporation
Hancock Whitney Corporation has entered into a definitive agreement to acquire Trustmark Corporation in an all-stock merger. Trustmark shareholders will receive 0.7463 shares of Hancock Whitney common stock for each share of Trustmark they own. Following the merger, Trustmark Bank will be merged into Hancock Whitney Bank, and five Trustmark directors will join the Hancock Whitney board.
Independent Bank Corp. filed an investor presentation deck to be used at the Piper Sandler Financial Services Conference on November 17, 2026. The presentation highlights the company's $25.0 billion in total assets, its recent acquisition of Enterprise, and record operating EPS of $1.90 for the third quarter of 2026.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
MIRA Pharmaceuticals announced new pharmacological findings for its investigational oral drug candidate MIRA-55, demonstrating high receptor selectivity for CB2 over opioid and COX receptors. The expanded screening showed a 500-fold separation from opioid receptor interactions, supporting its development as a differentiated non-opioid treatment for inflammatory pain. The company is currently advancing IND-enabling activities with a target submission date in the first half of 2027.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.
Entrepreneur Universe Bright Group Financial Results
Entrepreneur Universe Bright Group reported Q3 2026 revenue of $0.68 million, a decrease from $1.22 million in the prior year period, resulting in a net loss of $0.22 million. The company noted contracting demand in certain consulting lines but saw initial contributions from its newly established Credit Services segment in Hong Kong.
Term
Q3 2026
“Our third quarter results reflected contracting demand in certain consulting service lines, while digital marketing services and our newly established Credit Services segment contributed revenue during the period. We will continue to manage our operations prudently, strengthen our service capabilities and pursue opportunities to expand our revenue base in line with our long-term business objectives.”
Independence Realty Trust, Inc. (IRT) has filed a slide presentation to be used in various upcoming investor meetings beginning November 16, 2026. The presentation is furnished under Item 7.01 as a Regulation FD disclosure to provide strategic and operational updates to the investment community.
W.W. Grainger $400M Debt Financing with J.P. Morgan Securities LLC
W.W. Grainger, Inc. priced an underwritten public offering of $400 million in 5.400% Senior Notes due 2031. The company entered into an underwriting agreement with J.P. Morgan, U.S. Bancorp, and Wells Fargo, with the offering expected to close on November 19, 2026.
Value
$400M
Counterparty
J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC
Kyntra Bio reported Q3 2026 financial results, highlighting a cash position of $44.1 million and a runway extended into 2028. The company announced the discontinuation of its FG-3246 and FG-3180 programs due to insufficient efficacy, shifting focus toward a planned Phase 3 trial for roxadustat in early 2027. Additionally, the company restructured a royalty financing agreement, reducing its maximum payment obligation by $60 million.
Term
Q3 2026
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”
Thane Wettig, Chief Executive Officer of Kyntra Bio
Treasure Global Inc. implemented a 1-for-24 reverse stock split of its common stock effective November 16, 2026. The action is primarily intended to increase the per-share trading price to regain compliance with the Nasdaq minimum bid price requirement of $1.00 per share. The split reduced the company's outstanding shares from approximately 22 million to approximately 0.9 million.
Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.
Public Storage announced that it has posted an investor presentation to its website on November 16, 2026. The company intends to use this presentation at an upcoming investor conference to provide strategic and operational updates to the market.
Cardlytics announced a workforce reduction of approximately 30 employees, or 15% of its staff, as part of a broader cost-reduction initiative. The company expects to incur $0.7 million in non-recurring severance charges while achieving approximately $12.2 million in annualized operating expense savings. The restructuring is expected to be substantially complete by the end of the fourth quarter of 2026.
Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.
374Water Inc. reported a significant revenue increase to $3.47 million for the nine months ended September 30, 2026, compared to $1.90 million in the prior year period. Despite improved gross margins, the company incurred a net loss of $10.53 million due to high operating expenses and a $1.02 million loss on debt extinguishment.
SBIG Holdings, Inc. reported a net income of $3.2 million for the quarter ended September 30, 2026, primarily driven by a $1.7 million gain from discontinued operations and a $1.6 million gain on troubled debt restructuring. The company transferred its operating subsidiary, SpringBig, Inc., in July 2026 and currently has no operating business or revenue as it seeks a strategic transaction.
Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.
Term
Q3 2026
“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”
Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
For the nine months ended September 30, 2026, FS Credit Real Estate Income Trust reported net income of $98.8 million, a decrease from $129.6 million in the prior year period. Total assets decreased to $11.4 billion from $11.8 billion at year-end 2025, primarily driven by a reduction in mortgage loans held in securitization trusts.
First Breach, Inc. reported a significant increase in net loss to $53.8 million for the nine months ended September 30, 2026, driven by a surge in selling, general, and administrative expenses and stock-based compensation. Despite revenue growth to $0.93 million, the company maintains a negative gross margin and is currently operating as an early-stage, pre-net income entity.
International Land Alliance Inc. reported net revenues of $2.20 million for the nine months ended September 30, 2026, but incurred a net loss of $8.27 million due to high general and administrative expenses and interest costs. The company's total assets remained stable at approximately $32.36 million, while stockholders' equity increased to $8.85 million following significant common stock issuances and debt conversions.
Nasdaq EVP, CIO Bradley J. Peterson Sells $545K of Stock
Bradley J. Peterson, EVP, CIO, sold 5,000 shares of Nasdaq, Inc. at $109.07 a share, worth $545K in total on Nov 12, 2026. Shares held after the trade: 104,306 (-4.6%).
Lifevantage Director Michael A. Beindorff Sells $48.9K of Stock
Michael A. Beindorff, Director, sold 10,000 shares of Lifevantage Corp at $4.89 a share, worth $48.9K in total on Nov 12, 2026. Shares held after the trade: 31,625 (-24.0%).
Dyne Therapeutics CFO Erick Lucera Sells $33.5K of Stock
Erick Lucera, CFO, sold 1,991 shares of Dyne Therapeutics, Inc. at $16.82 a share, worth $33.5K in total on Nov 13, 2026. Shares held after the trade: 117,775 (-1.7%).
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.64M of Stock
Japan Post Holdings Co. Ltd. sold 12,900 shares of Aflac Inc at $126.76 to $129.08 a share (average $126.99) in 3 transactions, worth $1.64M in total on Nov 12, 2026. Shares held after the trade: 50,095,429 (-0.0%).
Fennec Pharmaceuticals Director Marco Maria Brughera Sells $240K of Stock
Marco Maria Brughera, Director, sold 20,000 shares of Fennec Pharmaceuticals Inc. at $12.00 a share, worth $240K in total on Nov 13, 2026. Shares held after the trade: 0 (-100.0%).
TheRealReal CAO Steve Ming Lo Sells $1.04M of Stock
Steve Ming Lo, CAO, sold 73,298 shares of TheRealReal, Inc. at $14.20 to $14.27 a share (average $14.23) in 2 transactions, worth $1.04M in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 83,542 (-30.2%).
Concentra Group Holdings Parent Insider Greg M. Gilbert Sells $781K of Stock
Greg M. Gilbert sold 18,194 shares of Concentra Group Holdings Parent, Inc. at $42.90 a share, worth $781K in total on Nov 12, 2026. Shares held after the trade: 130,640 (-12.2%).
Soluna Holdings, Inc. is a non-accelerated filer and smaller reporting company focused on Bitcoin mining and high-performance computing (HPC) data centers. As of November 12, 2026, the company reported 258,827,640 shares of common stock outstanding and is expanding its services into GPU-as-a-Service and AI-related infrastructure.